Definitive Contract HHSN272201500010C

This is a $4,590,862.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Sorrento Therapeutics, Inc., a small disadvantaged business. The contract is for the "DEVELOPMENT OF IN VITRO FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES", which was a Broad Agency Announcement (BAA) research area. The contract has a period of performance through May 2, 2025...

This is a $18,576,013.05 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to the nonprofit research institute Access To Advanced Health Institute (AAHI), also known as Aahi, Idri, and Infectious Disease Research Institute. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant (AMR) infections, and emerging infectious...

This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Emory University. The $3,458,502.19 cost-no-fee contract is for "TARGETING THERAPEUTICS DEVELOPMENT TO RELIEVE BOTTLENECKS: OPTIMIZONG LEAD THERAPEUTIC COMPOUNDS AGAINST INFECTIOUS PATHOGENS." It has a period of performance through October 31, 2018. The contract is not designated as a set-aside. The contract has several...

This is a $30,704,925.57 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Achaogen, Inc., a for-profit organization. The contract was awarded on September 1, 2008, with a period of performance through August 27, 2016, and was not set aside for any specific business type. The contract was awarded under a Broad Agency Announcement (BAA) solicitation, BAA...

<p>This is a $25,119,949.00 cost plus fixed fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to MacroGenics, Inc. for the development of &quot;Dual Affinity Re-targeting Molecules for HIV-1 Suppression&quot;. The contract has an ultimate completion date of October 31, 2024 and is part of NIAID's Division of AIDS (DAIDS) program. No set-aside designation was used for this award.</p>

This is a $575,850.00 fixed-price delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the In Vitro Antimicrobial Assessments 2011-2018 indefinite-delivery, indefinite-quantity (IDIQ) contract. The contract was awarded to Access To Advanced Health Institute (AAHI), a nonprofit biotech research institute located in Seattle, Washington. The contract is for unspecified &quot;OTHER FUNCTIONS&quot; and does not have a set-aside designation. As a prime...

This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL), a leading contract research and manufacturing organization. The $548,977.00 cost-plus-fixed-fee contract is for the delivery of services in support of NIAID's infectious disease research and product development initiatives. This award is a task order under an existing Indefinite...

This $1,797,717.00 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the National Institutes of Health (NIH), to Intralytix Inc., a biotechnology company specializing in bacteriophage-based products. The contract is for the development of a &quot;Universal, Scalable Artificial Intelligence-Based Platform for Manufacturing High Titer Biopharmaceuticals&quot;, which aligns with...

This is a Cost Plus Fixed Fee delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), to Southern Research Institute, a non-profit organization. The contract, which has a ceiling value of $516,234.16, is for the identification of anti-HIV therapeutics and topical microbicides. It falls under NIAID's In Vitro Testing Resource for HIV Therapeutics and Topical Microbicides program. The contract...

This contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Icon Government And Public Health Solutions, Inc., a for-profit organization. The $113,678.00 contract is a delivery order under the &quot;Therapeutics Against Infectious Diseases Phase 1&quot; indefinite delivery/indefinite quantity (IDIQ) contract vehicle, which enables streamlined ordering of clinical trial and...